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The European monitoring of excess mortality for public 
health action (EuroMOMO) network monitors weekly 
excess all-cause mortality in 27 European countries or 
subnational areas. During the first wave of the coro-
navirus disease (COVID-19) pandemic in Europe in 
spring 2020, several countries experienced extraordi-
narily high levels of excess mortality. Europe is cur-
rently seeing another upsurge in COVID-19 cases, and 
EuroMOMO is again witnessing a substantial excess 
all-cause mortality attributable to COVID-19.
The coronavirus disease (COVID-19) global pandemic 
is ongoing, with Europe and the Americas the current 
epicentres of transmission. As at 1 January, 2021, over 
82 million cases and 1.8 million deaths have been 
reported globally [1,2]. In Europe alone, the number 
of cases reported has now passed 26 million, with 
over 580,000 laboratory-confirmed COVID-19 deaths 
[3,4]. As many COVID-19 cases and deaths may not 
be confirmed by virological testing, and as the pan-
demic causes a range of indirect and collateral harms, 
the officially reported figures of laboratory-confirmed 
COVID-19 cases and deaths represent only a part of 
the total disease, mortality and overall public health 
burden associated with the pandemic. Here we report 
some noteworthy estimates of a marked increase in 
excess all-cause mortality in Europe coinciding with 
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a steep second wave of COVID-19 in many countries 
since September 2020.
Excess all-cause mortality during the first 
COVID-19 pandemic wave in Europe
The framework and methodology of the EuroMOMO 
network has been described earlier. Briefly, partici-
pating countries obtain weekly data on the number 
of all-cause deaths from civil registers or other offi-
cial sources in nearly real-time. The all-cause excess 
deaths are defined as the observed minus the expected 
numbers of deaths, and are estimated by participat-
ing countries or subnational areas (federal states/cit-
ies) using the EuroMOMO statistical algorithm [5]. The 
EuroMOMO hub compiles these outputs then performs 
a weekly secondary pooled analysis using an age-strat-
ified method [6], which generates a timely estimate 
that determines whether there were more deaths than 
expected in any one week.
The first wave of COVID-19 in spring 2020 was shown 
to be temporally associated with very high numbers of 
excess all-cause deaths in several individual European 
countries, as reported by the EuroMOMO network 
or its member countries [7-13]; most participating 
EuroMOMO countries implemented lockdowns during 
this time. During the summer period, COVID-19 case 
and death numbers were relatively low in general and 
social and physical distancing, as well as other public 
health measures, were relaxed in many countries [1]. 
In autumn 2020, the weekly number of COVID-19 cases 
again increased from approximately 341,000 total 
cases in week 40 (starting on 28 September) to 1.37 
million cases in week 45 (starting on 2 November) in 
the countries participating in the EuroMOMO network 
(Figure 1). 
Estimating excess all-cause mortality 
during second wave of COVID-19 in 
Europe
By the end of December 2020, the following 27 European 
countries or subnational areas had contributed their 
weekly mortality data: Austria, Belgium, Cyprus, 
Denmark, Estonia, Finland, France, Germany (Berlin 
and Hesse), Greece, Hungary, Ireland, Israel, Italy (19 
cities), Luxembourg, Malta, the Netherlands, Norway, 
Portugal, Slovenia, Spain, Sweden, Switzerland and 
the United Kingdom (UK) (England, Northern Ireland, 
Scotland, Wales). Details of participating countries are 
available on the EuroMOMO website [14].
Weekly numbers of excess all-cause deaths were esti-
mated for the total population (all ages) and for age 
groups 0–14, 15–44, 45–64, 65–74, 75–84 and ≥  85 
years. Furthermore, the number of weekly all-cause 
excess deaths was estimated from week 1 2020 up to 
and including week 53 2020, and compared with the 
mortality estimates from the previous 3 years (2017, 
2018 and 2019), based on data received in week 1 
2021. A country-specific adjustment function was 
applied to correct for the typical delay in registrations 
of deaths. Nonetheless, estimates of excess number 
of deaths for the most recent weeks are reported with 
some uncertainty and should be interpreted with cau-
tion (see more at [14]). Z-scores were applied to define 
and compare the excess mortality estimates.
Excess mortality in the countries
During the second wave of COVID-19 transmission in the 
European Region, the all-cause mortality increased to a 
consistent and substantial level (exceeding 4 z-scores 
above baseline) initially in Israel around week 37 2020, 
followed by Spain in week 41, then by Italy (19 cities) 
and the Netherlands in week 42. Soon after, substan-
tially increased excess mortality was also observed in 
Austria, Belgium, England, France, Greece, Hungary, 
Portugal, Slovenia and Switzerland. Denmark, Hesse 
(German federal state), Luxembourg, Scotland, Sweden 
and Wales have also observed some substantial excess 
mortality, but so far only as spikes. Meanwhile, sev-
eral other countries or subnational areas had, by week 
53, seen no or only limited excess mortality: Cyprus, 
Estonia, Finland, Berlin (German federal state), Ireland, 
Malta, Northern Ireland and Norway.
Pooled excess mortality for participating 
countries
The pooled estimates of all-cause deaths for the 27 
participating European countries or subnational areas 
during the second wave of COVID-19 show an overall 
consistent and substantial increase in excess all-cause 
mortality from week 40 2020 (Figure 2), though there 
was a spike in week 38 2020. Excess mortality was 
highest among individuals aged ≥ 65 years, but we also 
Figure 1
Weekly number of COVID-19 cases reported to the World 
Health Organization by the countries participating in the 

















COVID-19: coronavirus disease; EuroMOMO: European monitoring 
of excess mortality for public health action; WHO: World Health 
Organization.
a Detailed information about participating countries can be found 
on the EuroMOMO website [14].
Data updated on 7 January 2021. National data on COVID-19 
cases reported to WHO represent the entire country, not just 
subnational areas, as is the case for the mortality data reported 
to EuroMOMO from some countries (e.g. Germany and Italy).
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observed substantial excess deaths among individuals 
aged 45–64 years. Low levels of increased excess mor-
tality were seen in younger adults aged 15–44 years, 
while no excess mortality was seen in children aged 
0–14 years.
As at week 1 2021, our pooled estimates showed for 
the second COVID-19 wave a peak number of 15,392 
excess all-cause deaths for all ages in week 46, cor-
responding to a z-score of 24.8. Although this is very 
high, this excess mortality level is still lower than the 
peak reached during the first wave of COVID-19 in week 
14 2020, when the pooled excess mortality reached 
35,408 deaths for all ages (z-score = 55), as seen 
in Figure 3. 
Ethical statement
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Discussion
Excess all-cause mortality is widely recognised as 
a robust and comparable proxy for the total COVID-
19–associated mortality in the population [15]. Based 
on long-standing experience of timely monitoring 
of weekly excess all-cause mortality across many 
European countries, the EuroMOMO network was able 
to promptly detect, quantify and report the full mortal-
ity impact associated with COVID-19 during the first 
wave in early 2020 [16].
The rapid increase in excess all-cause deaths seen in 
autumn 2020 was unusual for that time of year. Such a 
pattern of excess mortality is usually seen later in the 
autumn and during winter, and is associated with the 
seasonal transmission of influenza virus. The last time 
an early excess mortality was seen was in 2009, asso-
ciated with the 2009 influenza A(H1N9) pandemic.
Figure 2
EuroMOMO pooled estimates of all-cause mortality (A) for all ages and (B–G) by age group, 27 participating countriesa or 
subnational areas, weeks 1 to 53 2020
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EuroMOMO: European monitoring of excess mortality for public health action.
a Detailed information about participating countries can be found on the EuroMOMO website [14].
b Substantial excess mortality is defined as an excess of four z-scores or higher than the expected baseline level.
c The last 3 weeks are marked in yellow, as there is some uncertainty about the estimates (as they were adjusted for typical delays in 
registrations of deaths).
Data updated on 7 January 2021. Please note the different scales of the y axes.
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Similarly to spring 2020, the increase in excess deaths 
in Europe in the second wave of the COVID-19 pandemic 
has been observed in the age groups 45–64 years, 
65–74 years, 75–84 years and ≥ 85 years. Nevertheless, 
some excess mortality has also been seen in individ-
uals aged 15–44 years, but to a much smaller extent 
than among the older age groups. No excess mortality 
has been observed in children 0–14 years.
The estimates presented here represent excess all-
cause deaths. As pointed out previously, in the absence 
of any major public health events other than the steep 
increase in reported COVID-19 cases, and with very low 
levels of seasonal influenza in the participating coun-
tries at present, the estimated excess mortality can 
be primarily attributed to the impact of the COVID-19 
pandemic, either directly or indirectly [15]. Although 
our mortality estimates for weeks 51, 52 and 53 are 
uncertain and should be interpreted with caution, as 
our applied adjustment for the typical delay in registra-
tions may be imprecise, we conclude that there was a 
consistent and substantial increase in excess mortal-
ity from week 40 2020 onwards. The delay in mortality 
following infection might even increase the observed 
mortality over the next few weeks.
Conclusions
Our findings are a warning signal of the serious impact 
the evolving second wave of COVID-19 could have on 
mortality, as seen in many European countries. With a 
maximum z-score of 24.8, pooled mortality has not yet 
reached the same level as observed during the peak 
of the first wave in spring 2020 (maximum z-score 55) 
and COVID-19 transmission has seemed to stabilise in 
some European countries, associated with strength-
ening of control measures. However, it is important to 
note that mortality increases lag increases in cases. 
Indeed, the mortality level observed during the sec-
ond wave of COVID-19 is already higher than the mor-
tality peak seen during the severe influenza season in 
Europe in 2017/18. There is a strong need for continued 
attention and public health action to avoid a worsen-
ing situation. The recent commencement of a rolling 
programme of targeted vaccination against COVID-19 
offers the prospect of significant blunting of excess all-
cause mortality in 2021.
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